|Articles|September 1, 2003

Using bisphosphonates to treat PCa-related bone events

Author(s)E. David Crawford, MD, Shandra Wilson, MD

Prostate cancer is the most prevalent non-cutaneous cancer diagnosed in men today, still accounting for a significant amount of morbidity and mortality in spite of increased screening efforts and advances in treatment.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

ByAdam B. Weiner, MD,Tyler Seibert, MD, PhD

August 21st 2026

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

ByHannah Clarke

August 21st 2026

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

ByJonathan Rubenstein, MD,Mark Painter

August 21st 2026

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

ByKari A.O. Tikkinen, MD, PhD

August 21st 2026

The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C

ByJoy Maulik, CRNP,Susanne A. Quallich, PhD, ANP-BC, NP-C, CUNP, CMHE, FAUNA, FAANP

August 20th 2026

Latest CME

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Using bisphosphonates to treat PCa-related bone events

Related Content

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Radioligand Therapy 101: The Science Behind the Strategy

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care